A recent Phase 1 clinical trial published in Cancer Cell has shown promising results in the treatment of metastatic cancer using an engineered antibody. The study involved injecting the antibody directly into the tumors of 12 patients, resulting in significant tumor reduction in six patients, including two cases of complete remission. This breakthrough has the potential to revolutionize treatment options for advanced cancer patients.
Katelyn Byrne, a cancer biologist at Oregon Health and State University, expressed her excitement about the study’s findings, stating, “Seeing this in humans is really great news. Especially for patients where we don’t have any options on the table, to be able to put this on the table now — it’s amazing.”
The research highlights the importance of stimulating the immune system to attack cancer cells, offering new hope for patients with limited treatment options. The results of this study could pave the way for the development of innovative therapies that target metastatic cancer more effectively.
While this groundbreaking research holds immense promise, access to the full article is exclusive to STAT+ subscribers. Subscribing to STAT+ will provide you with access to in-depth analysis, newsletters, premium events, and news alerts. To unlock the full content of this article and stay informed about the latest advancements in cancer research, consider subscribing to STAT+ today.
